

Synthesis and characterization of substituted bisbenzoxazine as potent antimicrobial agent

Kishor R. Lalcheta*, Bhvin B. Dhaduk, Jaymin P. Mendapara

Department of Biochemistry, Saurashtra University, Rajkot-360005, Gujarat, India

*E-mail address: kishor_kishor2000@yahoo.com

ABSTRACT

Bisbenzoxazines derivatives were synthesized by refluxing substituted bisphenol-C, substituted aniline and formaldehyde in presence of 1,4-dioxane with good yields. All the synthesized compounds were characterized by mass, NMR and IR and also evaluated for antimicrobial activity against four different bacterial and two fungal strains. The compounds 1c, 1h, 1j and 1l has found comparatively good active against all the bacterial strains.

Keywords: Benzoxazines; Synthesis; Microbial activity; Spectral techniques

1. INTRODUCTION

Benzoxazines are six-membered heterocyclic compounds synthesized via Mannich condensation reaction from phenols, amines, and formaldehyde. The first benzoxazine compound was synthesized by Holly and Cope in 1944 [1]. Later, the study on benzoxazines and their oligomers was further conducted from the 1950s to 1970s [2-4]. These benzoxazines were synthesized from monophenols, monoamines, and formaldehyde, but they could not form polymers with high molecular weight.

After benzoxazines based on bisphenol-A were synthesized [5,6], a series of bifunctionalbenzoxazines have been prepared from bisphenols (or monophenols), monoamines (or diamines), and formaldehyde [7-15]. The bifunctionalbenzoxazines can form into polybenzoxazines with high molecular weight via thermally activated ring-opening polymerization reaction [16-19], and the resultant polybenzoxazines possess excellent properties, such as relatively high glass transition temperature, superior mechanical properties, excellent electrical insulation properties, low moisture absorption, high thermal stability, high char yields, and low flammability.

Therefore, benzoxazines can be used as high-performance matrices in electronics and aerospace industries. The work on microbial screening has not been found on bisbenzoxazine derivatives. The aim of this study is to investigate the biological activity of substituted bisbenzoxazine derivatives.

2. EXPERIMENTAL

All research chemicals were purchased from Allied Chemicals (Vadodara) and used as received. Thin-layer chromatography was accomplished on 0.2 mm percolated plates of silica gel G60 F254 (Merck). Visualization was made with UV light (254 and 365 nm). IR spectra were recorded on a FT-IR-8400 spectrophotometer using DRS prob. ^1H (400 MHz) and ^{13}C (400 MHz) NMR spectra were recorded on a Bruker AVANCE II spectrometer in CDCl_3 . Chemical shifts are expressed in δ ppm downfield from TMS as an internal standard. Mass spectra were determined using direct inlet probe on a GCMS-QP 2010 mass spectrometer (Shimadzu). Melting points were measured in open capillaries and are uncorrected.

2. 1. General procedure for the synthesis of substituted bisbenzoxazine derivatives (2a-t)

0.1 mol substituted aniline in 20 ml 1,4-dioxane was slowly added to 0.2 mol formaldehyde in 80 ml, keeping temperature below $10\text{ }^\circ\text{C}$ in an ice bath. The mixture was stirred for 10 min and 0.05 mol bisphenol in 50 ml 1,4-dioxane was added. Temperature of the mixture was raised and refluxed for 15h, cooled, poured in the crushed ice, separated yellowish solid filtered, washed well with water and dried at room temperature. Crude product was treated with 3N NaOH solution till unreacted bisphenol was removed completely by intement checking with a dilute HCl solution washed well with water and dried at $50\text{ }^\circ\text{C}$. Compounds were recrystallized repeatedly from appropriate solvent system to get pure product **1(a-l)**.

2. 2. Biological testing

Bisphenol-C derivatives were screened for their *invitro* antibacterial and antifungal activities following micro broth dilution method [20-22]. Antibacterial activity was screened against gram-negative (*Bacillussubtilis*, *Staphylococcus aureus*) and gram-positive (*Escherichia coli*, *Salmonella typhi*) microorganisms. Antifungal activity was screened against *Aspergillusniger*, *Aspergillusclavatus* microorganisms. The standard drugs used for this study were gentamycin, ampicillin, chloramphenicol, ciprofloxacin and norfloxacin were used for antibacterial screening.


Nystatin and griseofulvin were used for antifungal screening. The standard strains used for screening of antibacterial and antifungal activities were procured from Institute of Microbial Technology (IMTECH), Chandigarh, India. Mueller Hinton Broth was used as a nutrient medium for bacteria and Sabouraud Dextrose Broth for fungal growth. Inoculums size for test strain was adjusted to 10^8 CFU/mL by comparing the turbidity. The results were recorded in the form of primary and secondary screening. The stock solution (2000 $\mu\text{g/mL}$) of the compounds under investigation and standard drugs were prepared by successive dilution. In primary screening, 1000, 500 and 250 $\mu\text{g/mL}$ concentrations of the compounds were used. The compounds which found active in this primary screening were further screened. In secondary screening, 200, 100, 50, 25, 12.5 and 6.25 $\mu\text{g/mL}$ concentrations were used. The inoculated wells were incubated overnight at $37\text{ }^\circ\text{C}$ in a humid atmosphere overnight. The highest dilution showing at least 99 % inhibition was considered as minimum inhibition concentration (MIC).

The investigation of antibacterial and antifungal screening data revealed that all the tested compounds 4a-t showed moderate to potent activity. The compounds 4i, 4k and 4l showed comparatively good activity against all the bacterial strains.

3. RESULTS AND DISCUSSION

3. 1. Chemistry

In our current research bisbenoxazine derivatives were synthesized by refluxing substitutedbisphenol-C, substituted aniline and formaldehyde in presence of 1,4-dioxane (Scheme 1). These compounds were characterized by FTIR, ^1H NMR, ^{13}C NMR, and MS techniques.



Scheme 1. Synthesis of bisbenoxazine derivatives.

Table 1. Substituted anilines and bisphenol-C used for the synthesis of bisbenoxazine derivatives.

Code	R	R ₁	RT (h)	% yield	Rf values
1a	H	H	15	83	0.63(B)
1b	H	OCH ₃	10	78	0.74(A)
1c	H	OH	10	80	0.69(A)
1d	H	NO ₂	10	94	0.82(A)
1e	CH ₃	H	10	89	0.78(A)
1f	CH ₃	Cl	15	93	0.61(B)
1g	CH ₃	NO ₂	15	91	0.70(B)
1h	CH ₃	Br	10	84	0.64(B)

1i	Cl	H	10	87	0.64(A)
1j	Cl	OCH ₃	10	93	0.74(A)
1k	Br	H	10	94	0.63(A)
1l	Br	OH	10	87	0.75(A)

3. 2. Spectroscopic data for the compounds 1(a-l)

6,6'-(cyclohexane-1,1-diyl)bis(3-phenyl)-3,4-dihydro-2H-benzo[e][1,3]oxazine (1a):

White solid, mp 185-187 °C; IR (KBr): 3459, 3327, 3193, 2999, 1648, 1586, 1261, 1061 cm⁻¹; ¹H NMR (400 MHz, Chloroform) δ 7.33 – 7.28 (m, 2H), 7.27 – 7.09 (m, 6H), 7.08 – 6.92 (m, 2H), 6.77 – 6.66 (m, 6H), 6.02 – 5.98 (m, 2H), 5.44 – 5.40 (m, 2H), 4.85 – 4.81 (m, 2H), 4.78 – 4.74 (m, 2H), 1.82 – 1.78 (m, 2H), 1.72 (t, *J* = 9.4 Hz, 3H), 1.46 – 1.36 (m, 5H); MS (*m/z*): 502 (M⁺); Anal. Calcd for C₃₄H₃₄N₂O₂: C, 81.24; H, 6.82; N, 5.57; O, 6.37; Found: C, 81.20; H, 6.80; N, 5.52; O, 6.33.

6,6'-(cyclohexane-1,1-diyl)bis(3-(4-methoxyphenyl)-3,4-dihydro-2H-benzo[e][1,3]oxazine) (1b):

Yellow solid; mp 180-184 °C; IR (KBr): 3452, 3307, 3223, 2980, 1653, 1509, 1461, 1051 cm⁻¹; ¹H NMR: δ 1.37-1.44 (m, 6H, cyclohexane -CH₂), 1.70-1.78 (t, 4H, cyclohexane -CH₂), 3.83 (s, 6H, -OCH₃), 4.61 (s, 4H, -NCH₂), 6.00 (s, 4H, -OCH₂), 6.65 (m, 4H, Ar-H), 6.79-6.81(m, 6H, Ar-H), 7.00-7.06(m, 4H, Ar-H); MS (*m/z*): 562 (M⁺); Anal. Calcd for C₃₆H₃₈N₂O₄: C, 76.84; H, 6.81; N, 4.98; O, 11.37; Found: C, 76.80; H, 6.78; N, 4.96; O, 11.33.

6,6'-(cyclohexane-1,1-diyl)bis(3-(4-hydroxyphenyl)-3,4-dihydro-2H-benzo[e][1,3]oxazine) (1b):

Yellow solid; mp 210-212 °C; IR (KBr): 3412, 3317, 3253, 2950, 1613, 15039, 1431, 1041 cm⁻¹; ¹H NMR: δ 1.37-1.44 (m, 6H, cyclohexane -CH₂), 1.70-1.78 (t, 4H, cyclohexane -CH₂), 3.83 (s, 6H, -OCH₃), 4.61 (s, 4H, -NCH₂), 5.35 (s, 2H, -OH), 6.00 (s, 4H, -OCH₂), 6.59 (m, 4H, Ar-H), 6.77-6.79 (m, 6H, Ar-H), 7.00-7.06 (m, 4H, Ar-H); MS (*m/z*): 534 (M⁺); Anal. Calcd for C₃₄H₃₄N₂O₄: C, 76.38; H, 6.41; N, 5.24; O, 11.97; Found: C, 76.34; H, 6.41; N, 5.24; O, 11.95.

6,6'-(cyclohexane-1,1-diyl)bis(3-(4-nitrophenyl)-3,4-dihydro-2H-benzo[e][1,3]oxazine) (1d)

Yellow solid; mp 194-196 °C; IR (KBr): 3412, 3317, 3253, 2950, 1613, 1539, 1431, 1061 cm⁻¹; ¹H NMR: δ 1.37-1.44 (m, 6H, cyclohexane -CH₂), 1.70-1.78 (t, 4H, cyclohexane -CH₂), 3.83 (s, 6H, -OCH₃), 4.61 (s, 4H, -NCH₂), 6.00 (s, 4H, -OCH₂), 6.79 (d, 2H, Ar-H), 7.00-7.06 (m, 8H, Ar-H), 8.08 (m, 4H, Ar-H); MS (*m/z*): 592 (M⁺); Anal. Calcd for C₃₄H₃₂N₄O₆: C, 68.91; H, 5.44; N, 9.45; O, 16.20; Found: C, 68.88; H, 5.40; N, 9.40; O, 16.20.

6,6'-(cyclohexane-1,1-diyl)bis(3-phenyl-7-methyl)-3,4-dihydro-2H-benzo[e][1,3]oxazine (1e)

white solid; mp 194-196 °C; IR (KBr): 3449, 3331, 3182, 3055, 2952, 1651, 1568, 1491, 1247, 1049 cm⁻¹; ¹H NMR: δ 1.37-1.44 (m, 6H, cyclohexane -CH₂), 1.70-1.78 (t, 4H,

cyclohexane -CH₂), 2.34 (s, 6H, CH₃), 4.61 (s, 4H, -NCH₂), 5.35 (s, 2H, -OH), 6.00 (s, 4H, -OCH₂), 6.79-6.81 (m, 4H, Ar-H), 6.94 (m, 6H, Ar-H), 7.27 (m, 4H, Ar-H); MS (*m/z*): 530 (M⁺); Anal. Calcd for C₃₆H₃₈N₂O₂: C, 81.47; H, 7.22; N, 5.28; O, 6.03; Found: C, 81.40; H, 7.20; N, 5.25; O, 6.00.

6,6'-(cyclohexane-1,1-diyl)bis(3-(4-chlorophenyl-7-methyl)-3,4-dihydro-2H-benzo[e][1,3]oxazine)(1f)

White solid; mp 245-247 °C; IR (KBr): 3442, 3226, 3143, 2986, 1642, 1566, 1241, 1061 cm⁻¹; 1H NMR: δ 1.37-1.44 (m, 6H, cyclohexane -CH₂), 1.70-1.78 (t, 4H, cyclohexane -CH₂), 2.34 (s, 6H, CH₃), 4.61 (s, 4H, -NCH₂), 6.00 (s, 4H, -OCH₂), 6.70 (d, 4H, Ar-H), 6.81 (s, 2H, Ar-H), 6.94 (s, 2H, Ar-H), 7.31 (d, 4H, Ar-H); MS (*m/z*): 599 (M⁺); Anal. Calcd for C₃₆H₃₆Cl₂N₂O₂: C, 72.11; H, 6.05; Cl, 11.83; N, 4.67; O, 5.34; Found: C, 72.09; H, 6.00; Cl, 11.80; N, 4.63; O, 5.30.

6,6'-(cyclohexane-1,1-diyl)bis(3-(4-nitrophenyl-7-methyl)-3,4-dihydro-2H-benzo[e][1,3]oxazine) (1g)

White solid; mp 165-167 °C; IR (KBr): 3462, 3327, 3220, 2980, 1623, 1509, 1461, 1051 cm⁻¹; 1H NMR: δ 1.37-1.44 (m, 6H, cyclohexane -CH₂), 1.70-1.78 (t, 4H, cyclohexane -CH₂), 2.34 (s, 6H, CH₃), 4.61 (s, 4H, -NCH₂), 6.00 (s, 4H, -OCH₂), 6.81 (s, 2H, Ar-H), 6.94 (s, 2H, Ar-H), 7.02 (d, 4H, Ar-H), 8.08 (d, 4H, Ar-H); MS (*m/z*): 620 (M⁺); Anal. Calcd for C₃₆H₃₆N₄O₆: C, 69.66; H, 5.85; N, 9.03; O, 15.47; Found: C, 69.60; H, 5.82; Cl, N, 9.00; O, 15.45.

6,6'-(cyclohexane-1,1-diyl)bis(3-(4-bromophenyl-7-methyl)-3,4-dihydro-2H-benzo[e][1,3]oxazine) (1h)

White solid; mp 256-258 °C; IR (KBr): 3459, 3252, 3143, 2919, 1648, 1586, 1241, 1051 cm⁻¹; 1H NMR: δ 1.37-1.44 (m, 6H, cyclohexane -CH₂), 1.70-1.78 (t, 4H, cyclohexane -CH₂), 2.34 (s, 6H, CH₃), 4.61 (s, 4H, -NCH₂), 6.00 (s, 4H, -OCH₂), 6.65 (d, 4H, Ar-H), 6.81 (s, 2H, Ar-H), 6.94 (s, 2H, Ar-H), 7.42 (d, 4H, Ar-H); MS (*m/z*): 688 (M⁺); Anal. Calcd for C₃₆H₃₆Br₂N₂O₂: C, 62.80; H, 5.27; Br, 23.21; N, 4.07; O, 4.65; Found: C, 62.78; H, 5.25; Br, 23.18; N, 4.03; O, 4.02.

6,6'-(cyclohexane-1,1-diyl)bis(3-phenyl-7-chloro)-3,4-dihydro-2H-benzo[e][1,3]oxazine) (1i)

White solid; mp 165-167 °C; IR (KBr): 3462, 3327, 3220, 2980, 1623, 1509, 1461, 1051 cm⁻¹; 1H NMR: δ 1.37-1.44 (m, 6H, cyclohexane -CH₂), 1.70-1.78 (t, 4H, cyclohexane -CH₂), 2.34 (s, 6H, CH₃), 4.61 (s, 4H, -NCH₂), 6.00 (s, 4H, -OCH₂), 6.79 (m, 2H, Ar-H), 6.94 (m, 4H, Ar-H), 6.99-7.00 (m, 4H, Ar-H), 7.27 (m, 4H, Ar-H); MS (*m/z*): 571 (M⁺); Anal. Calcd for C₃₄H₃₂Cl₂N₂O₂: C, 71.45; H, 5.64; Cl, 12.41; N, 4.90, O, 5.60; Found: C, 71.45; H, 5.64; Cl, 12.40; N, 4.85; O, 5.55.

6,6'-(cyclohexane-1,1-diyl)bis(3-(4-methoxyphenyl-7-chloro)-3,4-dihydro-2H-benzo[e][1,3]oxazine) (1j)

White solid; mp 178-180 °C; IR (KBr): 3442, 3327, 3173, 2989, 1653, 1586, 1261, 1061 cm⁻¹; 1H NMR: δ 1.37-1.44 (m, 6H, cyclohexane -CH₂), 1.70-1.78 (t, 4H, cyclohexane -CH₂), 2.34 (s, 6H, CH₃), 4.61 (s, 4H, -NCH₂), 6.00 (s, 4H, -OCH₂), 6.79 (m, 2H, Ar-H), 6.94 (m, 4H, Ar-H), 6.99-7.00 (m, 4H, Ar-H), 7.27 (m, 4H, Ar-H); MS (*m/z*): 631 (M⁺); Anal. Calcd for C₃₆H₃₆Cl₂N₂O₄: C, 68.46; H, 5.75; Cl, 11.23; N, 4.44; O, 10.13; Found: C, 68.40; H, 5.70; Cl, 11.20, N, 4.40, O, 10.09.

6,6'-(cyclohexane-1,1-diyl)bis(3-phenyl-7-bromo)-3,4-dihydro-2H-benzo[e][1,3]oxazine) (1k)

White solid; mp 240-242 °C; IR (KBr): 3420, 3226, 3143, 2988, 1632, 1546, 1231, 1061 cm⁻¹; ¹H NMR: δ 1.37-1.44 (m, 6H, cyclohexane -CH₂), 1.70-1.78 (t, 4H, cyclohexane -CH₂), 2.34 (s, 6H, CH₃), 4.61 (s, 4H, -NCH₂), 6.00 (s, 4H, -OCH₂), 6.79 (m, 2H, Ar-H), 6.94-6.95(m, 4H, Ar-H), 7.04 (s, 2H, Ar-H), 7.27(m, 4H, Ar-H); MS (*m/z*): 660 (M⁺); Anal. Calcd for C₃₄H₃₂Br₂N₂O₂: C, 61.83; H, 4.88; Br, 24.20; N, 4.24; O, 4.85; Found: C, 61.79; H, 4.84; Br, 24.15; N, 4.20; O, 4.80.

6,6'-(cyclohexane-1,1-diyl)bis(3-(4-hydroxyphenyl-7-bromo)-3,4-dihydro-2H-benzo[e][1,3]oxazine) (1l)

White solid; mp 194-196 °C; IR (KBr): 3412, 3317, 3253, 2950, 1613, 1539, 1431, 1061 cm⁻¹; ¹H NMR: δ 1.37-1.44 (m, 6H, cyclohexane -CH₂), 1.70-1.78 (t, 4H, cyclohexane -CH₂), 2.34 (s, 6H, CH₃), 4.61 (s, 4H, -NCH₂), 5.35 (s, 2H, -OH), 6.00 (s, 4H, -OCH₂), 6.59 (d, 4H, Ar-H), 6.77(d, 4H, Ar-H), 6.95 (s, 2H, Ar-H), 7.04 (s, 2H, Ar-H); MS (*m/z*): 692 (M⁺); Anal. Calcd for C₃₄H₃₂Br₂N₂O₄: C, 58.97; H, 4.66; Br, 23.08; N, 4.05; O, 9.24; Found: C, 58.94; H, 4.60; Br, 23.08; N, 4.05; O, 9.20.

Table 2. Microbial activity of bisphenol-C derivatives.

Compound	Antibacterial activity				Antifungal activity	
	<i>E. coli</i>	<i>S. typhi</i>	<i>B. subtilis</i>	<i>S. aureus</i>	<i>A. niger</i>	<i>A. clavattus</i>
	MTCC 443	MTCC 98	MTCC 441	MTCC 96	MTCC 282	MTCC 1323
1a	125	200	200	250	1000	250
1b	200	200	250	200	>1000	500
1c	62.5	100	125	200	500	500
1d	250	250	500	500	500	>1000
1e	250	200	500	250	1000	>1000
1f	125	250	250	500	500	>1000
1g	250	250	200	250	>1000	500
1h	100	200	62.5	250	100	500
1i	125	500	100	100	250	>1000
1j	62.5	125	250	200	250	>1000
1k	250	125	125	100	>1000	>1000
1l	62.5	250	200	200	1000	1000
Gentamycin	0.05	5	1	0.25	-	-

Ampicillin	100	100	250	250	-	-
Chloramphenicol	50	50	50	50	-	-
Ciprofloxacin	25	25	50	50	-	-
Norfloxacin	10	10	100	10	-	-
Nystatin	-	-	-	-	100	100
Griseofulvin	-	-	-	-	100	100

4. CONCLUSION

In summary, we have described the synthesis of substituted bisbenzoxazine derivatives in excellent yields by simple refluxing. The spectral data are incorporated with the structure of compounds **1a-1**. The antimicrobial data reported here which may be the better reference for the future research in the class of pyrimidine derivatives.

Acknowledgement

Author thankful to Department of Biochemistry, Saurashtra University for providing facilities and SAIF, Punjab University for instrumental support.

References

- [1] Holly F.W., Cope A. C., *J Am Chem Soc.* 66 (1944) 1875.
- [2] Burke W.J., Weatherbee C., *J Am Chem Soc.* 72 (1950) 4691.
- [3] Burke W.J., Stephens C.W. *J Am Chem Soc.* 74 (1952) 1518.
- [4] Burke W.J., Murdoch K.C, Ec. G., *J Am Chem Soc.* 76 (1954) 1677.
- [5] Ning X., Ishida H., *J PolymSci Part A.* 32 (1994) 1121.
- [6] Ning X., Ishida H., *J PolymSci Part B.* 32 (1994) 921.
- [7] Liu Y.F, Yue Z.Q, Gao J.G., *Polymer* 51 (2010) 3722.
- [8] Jia K., Xu M.Z., Zhao R., Liu X.B., *Polym Int.* 60 (2011) 414.
- [9] Chen K.C., Li H.T., Chen W.B., Liao C.H., Sun K.W., Chang F.C., *Polym Int.* 60 (2011) 436.
- [10] Li S.F, Wang L.L., *J Appl Polym Sci.* 99 (2006) 1359.
- [11] Lin C.H., Chang S.L., Hsieh C.W., Lee H.H., *Polymer* 49 (2008) 1220.
- [12] Sponto'n M., Larrechi M.S., Ronda J.C, Galia` M., Ca´diz V., *J Polym Sci Part A.* 46 (2008) 7162.
- [13] Andronesu C., Ga`rea S.A., Deleanu C., Iovu H., *Thermochim Acta* 530 (2012) 42.

- [14] Chozhan C.K, Alagar M, Gnanasundaram P., *Acta Mater.* 57 (2009) 782.
- [15] Chang S.L, Lin C.H. Facile., *J Polym Sci Part A.* 48 (2010) 2430.
- [16] Ishida H, Rodriguez Y., *Polymer* 36 (1995) 3151.
- [17] Russell V.M, Koenig J.L, Low H.Y, Ishida H., *J Appl Polym Sci.* 70 (1998) 1413.
- [18] Wang Y.X, Ishida H., *Polymer* 40 (1999) 4563.
- [19] Wang Y.X, Ishida H., *Macromolecules* 33 (2000) 2839.
- [20] National committee for clinical laboratory standards.,5th ed.; NCCLS: Wayne, PA, 2000.
- [21] Patel N. B., Shaikh A. R., *Indian J. Chem.* 49 (2010) 929.

(Received 13 October 2014; accepted 20 October 2014)